Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

66.04USD
26 May 2017
Change (% chg)

$-2.11 (-3.09%)
Prev Close
$68.15
Open
$67.93
Day's High
$68.37
Day's Low
$65.15
Volume
106,013
Avg. Vol
158,926
52-wk High
$75.44
52-wk Low
$26.56

Latest Key Developments (Source: Significant Developments)

Sage Therapeutics qtrly loss per share $1.52
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Sage Therapeutics Inc ::Sage therapeutics announces first quarter 2017 financial results and provides pipeline update.Qtrly loss per share $1.52.  Full Article

Sage Therapeutics posts Q4 loss per share of $1.50
Thursday, 23 Feb 2017 06:30am EST 

Sage Therapeutics Inc : Sage Therapeutics announces fourth quarter and full year 2016 financial results and provides corporate update . Expects existing cash, cash equivalents, to fund anticipated level of operations, based on its current operating plans, into Q2' 18 .Qtrly loss per share $1.50.  Full Article

Sage-547 granted prime designation by EMA for treatment of postpartum depression
Wednesday, 16 Nov 2016 09:40am EST 

Sage Therapeutics Inc : Sage-547 granted prime designation by EMA for the treatment of postpartum depression .Company now anticipates globalizing its PPD development program and establishing european clinical operations.  Full Article

Sage Therapeutics announces third quarter 2016 financial results
Thursday, 3 Nov 2016 06:30am EDT 

Sage Therapeutics Inc : Sage Therapeutics Inc announces third quarter 2016 financial results and provides SRSE European update . Qtrly net loss per share $1.15 . Sage Therapeutics says ongoing phase 3 status trial expected to be sufficient to support european marketing authorization application for SAGE-547 in SRSE . Sage Therapeutics Inc says eight clinical trials across pipeline expected to generate top-line data in 2017 . Sage Therapeutics says expects existing cash, cash equivalents, marketable securities will fund operating and capital expenditure requirements into Q2 2018 .Sage Therapeutics says advancing a portfolio of multiple, novel central nervous system product candidates targeting GABA and NMDA receptor systems.  Full Article

Sage Therapeutics Q2 EPS ($1.08)
Tuesday, 9 Aug 2016 06:30am EDT 

Sage Therapeutics Inc : Sage Therapeutics announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $1.08.  Full Article

Sage Therapeutics says completed enrollment for Phase 2 trial of Sage-547
Thursday, 26 May 2016 04:05pm EDT 

Sage Therapeutics Inc :SAGE THERAPEUTICS announces completion of enrollment for phase 2 proof-of-concept trial of sage-547 in severe postpartum depression.  Full Article

Sage Therapeutics Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:09pm EST 

Sage Therapeutics, Inc:commenced an underwritten public offering of $150 million of its common stock.SAGE also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock offered in the public offering.All of the shares in the offering are to be sold by SAGE.J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Partners LLC and Cowen and Company, LLC are serving as lead managers and Canaccord Genuity Inc. is serving as co-manager.  Full Article

SAGE Therapeutics announces positive top-line data in exploratory trial of SAGE-547 in Postpartum Depression
Tuesday, 9 Jun 2015 06:29am EDT 

SAGE Therapeutics Inc:Says marked improvement demonstrated in HAM-D scores in patients with ppd enrolled in open-label trial.Says plan to initiate placebo-controlled trial of sage-547 by year end.Says SAGE-547 was well-tolerated in patients treated with no serious adverse events.Says no serious adverse events were observed in patients on therapy or during the 30-day follow-up period.  Full Article

More From Around the Web

BRIEF-Sage Therapeutics qtrly loss per share $1.52

* Sage therapeutics announces first quarter 2017 financial results and provides pipeline update